We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Asthma Drug Meets Primary Goal in Phase III
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) along with Amgen (AMGN - Free Report) announced that their promising pipeline candidate tezepelumab met the primary endpoint in the phase III NAVIGATOR study, which evaluated the candidate for treating patients with severe, uncontrolled asthma.
Data from the study showed that treatment with tezepelumab plus standard of care (SoC) led to a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER), a measure of deterioration of asthma, over 52 weeks of treatment versus placebo plus SoC in the overall patient population.
Moreover, in patients with low levels of eosinophil (less than 300 cells per microlitre and less than 150 cells per microlitre) too, tezepelumab demonstrated a statistically significant and clinically meaningful reduction in AAER. Results from the study will be presented at an upcoming medical conference. Importantly, tezepelumab was well tolerated in patients suffering severe asthma.
Secondary endpoints of the NAVIGATOR study included the effect of tezepelumab on lung function, asthma control and health-related quality of life.
Shares of AstraZeneca have rallied 13.5% so far this year against the industry’s decrease of 0.8%.
We note that tezepelumab is an anti-thymic stromal lymphopoietin monoclonal antibody, currently being evaluated for the treatment of patients with severe, uncontrolled asthma.
In September 2018, the FDA granted a Breakthrough Therapy designation to tezepelumab for the treatment of patients with severe, uncontrolled asthma without an eosinophilic phenotype.
The NAVIGATOR study is part of the phase III PATHFINDER program on tezepelumab. Another study on tezepelumab in the phase III PATHFINDER program is SOURCE.
We note that the asthma market holds great potential. However, upon potential approval, tezepelumab is likely to face stiff competition from treatments like GlaxoSmithKline’s (GSK - Free Report) Nucala, which is approved for several indications, anmey severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.
Repligen’s earnings estimates have been revised 7.8% and 10.5% upward for 2020 and 2021 each over the past 60 days. The stock has skyrocketed 102.1% year to date.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
AstraZeneca's (AZN) Asthma Drug Meets Primary Goal in Phase III
AstraZeneca PLC (AZN - Free Report) along with Amgen (AMGN - Free Report) announced that their promising pipeline candidate tezepelumab met the primary endpoint in the phase III NAVIGATOR study, which evaluated the candidate for treating patients with severe, uncontrolled asthma.
Data from the study showed that treatment with tezepelumab plus standard of care (SoC) led to a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER), a measure of deterioration of asthma, over 52 weeks of treatment versus placebo plus SoC in the overall patient population.
Moreover, in patients with low levels of eosinophil (less than 300 cells per microlitre and less than 150 cells per microlitre) too, tezepelumab demonstrated a statistically significant and clinically meaningful reduction in AAER. Results from the study will be presented at an upcoming medical conference. Importantly, tezepelumab was well tolerated in patients suffering severe asthma.
Secondary endpoints of the NAVIGATOR study included the effect of tezepelumab on lung function, asthma control and health-related quality of life.
Shares of AstraZeneca have rallied 13.5% so far this year against the industry’s decrease of 0.8%.
We note that tezepelumab is an anti-thymic stromal lymphopoietin monoclonal antibody, currently being evaluated for the treatment of patients with severe, uncontrolled asthma.
In September 2018, the FDA granted a Breakthrough Therapy designation to tezepelumab for the treatment of patients with severe, uncontrolled asthma without an eosinophilic phenotype.
The NAVIGATOR study is part of the phase III PATHFINDER program on tezepelumab. Another study on tezepelumab in the phase III PATHFINDER program is SOURCE.
We note that the asthma market holds great potential. However, upon potential approval, tezepelumab is likely to face stiff competition from treatments like GlaxoSmithKline’s (GSK - Free Report) Nucala, which is approved for several indications, anmey severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.
Zacks Rank & Key Pick
AstraZeneca currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Repligen Corporation (RGEN - Free Report) , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Repligen’s earnings estimates have been revised 7.8% and 10.5% upward for 2020 and 2021 each over the past 60 days. The stock has skyrocketed 102.1% year to date.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>